\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Events

Combine to Conquer
 January 6, 2021

Fireside Chat with CEOs from five oncology biotech companies designed to explore the increasing but not completely novel trend of conducting clinical trials with new drugs in combination with existing standard-of-care therapies.